Metformina Viatris (Metformin Hydrochloride)

Metformin activates AMP‑activated protein kinase (AMPK), which suppresses hepatic glucose production, enhances peripheral insulin sensitivity, and reduces intestinal glucose absorption. These actions collectively lower circulating glucose without stimulating insulin secretion.

The dose of Metformina Viatris is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration.

Metformina Viatris is classified as pregnancy category B, indicating no evidence of fetal risk in animal studies but limited human data. It may be used during pregnancy if the benefits outweigh potential risks, and it is excreted in breast milk; breastfeeding mothers should consult their physician.

To order, submit an enquiry on the Metformina Viatris product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with sulfonylureas, metformin (Metformina Viatris) does not stimulate insulin release, resulting in a lower risk of hypoglycemia. It also promotes modest weight loss, whereas sulfonylureas can cause weight gain. Metformin is often first‑line therapy because of its efficacy, safety profile, and cardiovascular benefits.

Store Metformina Viatris at room temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Metformina Viatris is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water; they should not be crushed, chewed, or split unless the prescriber advises otherwise.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of unexplained fatigue, muscle pain, rapid breathing, or skin eruptions and seek immediate medical attention if they occur.

Metformina Viatris is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those receiving radiographic contrast studies when renal function is compromised.